Orthostatic Hypotension Drugs

Orthostatic Hypotension Drugs

Global Orthostatic Hypotension Drugs Market to Reach US$1.8 Billion by 2030

The global market for Orthostatic Hypotension Drugs estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Midodrine Drug, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$943.3 Million by the end of the analysis period. Growth in the Northera (Droxidopa) Drug segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$295.6 Million While China is Forecast to Grow at 12.5% CAGR

The Orthostatic Hypotension Drugs market in the U.S. is estimated at US$295.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$416.8 Million by the year 2030 trailing a CAGR of 12.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Orthostatic Hypotension Drugs Market - Key Trends and Drivers Summarized

Orthostatic hypotension, also known as postural hypotension, is a condition characterized by a significant drop in blood pressure when a person stands up from sitting or lying down, leading to symptoms like dizziness, lightheadedness, or even fainting. This condition can be particularly prevalent in the elderly or in individuals with certain neurological disorders such as Parkinson’s disease. The treatment for orthostatic hypotension primarily aims to increase blood pressure and improve blood flow. Drugs commonly used for this condition include midodrine, which activates receptors on the smallest arteries and veins to increase vascular tone and blood pressure, and fludrocortisone, which enhances sodium retention to increase fluid volume in the circulatory system. Additionally, non-pharmacological strategies such as increased salt intake, wearing compression stockings, and physical maneuvers are often recommended alongside medication.

The development of drugs for orthostatic hypotension has been relatively moderate, focusing on symptomatic management rather than cure. However, recent advances in understanding the underlying pathophysiological mechanisms of the condition have opened up possibilities for targeted drug therapies. Researchers are exploring the roles of various neurotransmitters and hormonal pathways in regulating blood pressure and vascular tone. This has led to investigational therapies that aim to modulate these pathways more precisely, potentially offering more effective and sustainable treatment options. For example, novel agents that can enhance the responsiveness of the autonomic nervous system or improve cardiac output are under study. Additionally, there is growing interest in using combination therapies that address multiple mechanisms contributing to orthostatic hypotension, thus providing a more holistic approach to treatment.

The growth in the orthostatic hypotension drugs market is driven by several factors, including an aging global population, increased prevalence of diabetes and heart diseases, and improved diagnostic techniques that lead to higher detection rates of the condition. With the rise in elderly populations, who are more susceptible to orthostatic hypotension due to physiological changes and comorbid conditions, there is a corresponding increase in the demand for effective treatments. Furthermore, advancements in medical technologies and diagnostics are enabling better identification and understanding of various forms of blood pressure dysregulation, including orthostatic hypotension, leading to more targeted interventions. Consumer behavior also influences this market, as patients seek treatments that offer quick relief from symptoms and improve quality of life without significant side effects. The development of new drugs that can safely be combined with existing hypertension medications is also a critical area of research, driven by the need to manage orthostatic hypotension in patients with complex health profiles. Collectively, these drivers ensure ongoing investments and innovations in the development of orthostatic hypotension treatments.

Select Competitors (Total 86 Featured) -

• Alembic Pharmaceuticals, Inc.
• Avalo Therapeutics, Inc
• Baxter International, Inc.
• CuraSen Therapeutics
• H. Lundbeck A/S
• Hikma Pharmaceuticals PLC
• Luye Pharma Group
• Manus Aktteva Biopharma LLP
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Theravance Biopharma, Inc.
• Upsher-Smith Laboratories LLC
• Viatris
• Zydus Lifesciences Limited

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.